[{"orgOrder":0,"company":"AmbioPharm","sponsor":"Upsher-Smith Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Partnership","leadProduct":"Corticotropin","moa":"Melanocortin receptor 2","graph1":"Neurology","graph2":"Approved FDF","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AmbioPharm \/ Upsher-Smith Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"AmbioPharm \/ Upsher-Smith Laboratories"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"ONL Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"AmbioPharm \/ ONL Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"AmbioPharm \/ ONL Therapeutics"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"OKYO Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"AmbioPharm \/ AmbioPharm","highestDevelopmentStatusID":"8","companyTruncated":"AmbioPharm \/ AmbioPharm"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"Adalvo","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"MALTA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AmbioPharm \/ AmbioPharm","highestDevelopmentStatusID":"15","companyTruncated":"AmbioPharm \/ AmbioPharm"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"Amytrx Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Partnership","leadProduct":"AMTX-100","moa":"NFkB","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"AmbioPharm \/ AmbioPharm","highestDevelopmentStatusID":"7","companyTruncated":"AmbioPharm \/ AmbioPharm"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Thrixopelma Pruriens Venom Peptide","moa":"NaV1.7 channel","graph1":"Neurology","graph2":"Undisclosed","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AmbioPharm \/ AmbioPharm","highestDevelopmentStatusID":"1","companyTruncated":"AmbioPharm \/ AmbioPharm"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"Adalvo","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"MALTA","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AmbioPharm \/ AmbioPharm","highestDevelopmentStatusID":"1","companyTruncated":"AmbioPharm \/ AmbioPharm"}]

Find Clinical Drug Pipeline Developments & Deals by AmbioPharm

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : ONL1204 Ophthalmic Solution is a novel, first-in-class small peptide Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs in a range of retinal diseases and conditions.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 07, 2022

                          Lead Product(s) : ONL1204

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : IND Enabling

                          Sponsor : ONL Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : The OK-101 drug candidate displays potent anti-inflammatory activity in animal models of DED. OK-101 also reduces Corneal Neuropathic Pain (CNP) in a ciliary nerve ligation animal model of CNP.

                          Product Name : Undisclosed

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          August 30, 2022

                          Lead Product(s) : Urcosimod

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Recipient : OKYO Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Amytrx has identified new opportunities for other inflammatory and metabolic diseases with attractive out-licensing and collaborative opportunities using its proprietary AMTX-100 human peptide platform.

                          Product Name : Undisclosed

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          July 26, 2022

                          Lead Product(s) : AMTX-100

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Amytrx Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          04

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Icatibant, a complex injectable peptide product, forming part of high-value product, is an equivalent and more affordable version of Firazyr (Takeda/Shire), used used to treat a serious orphan disease, acute attacks of hereditary angioedema.

                          Product Name : Icatibant Acetate-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 28, 2021

                          Lead Product(s) : Icatibant Acetate

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Recipient : Adalvo

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Researchers have utilized a venom peptide originally isolated from the Peruvian green velvet tarantula (Thrixopelma pruriens) that blocks Nav1.7 voltage-gated ion channels, an ion channel important in pain signaling.

                          Product Name : Undisclosed

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          July 20, 2021

                          Lead Product(s) : Thrixopelma Pruriens Venom Peptide

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Recipient : University of California

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : The partnership includes a basket of difficult-to-make peptide products that will be used to treat various diseases, ranging from diabetes to immunology disorders, cardiologic and endocrinology diseases.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          July 29, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Undisclosed

                          Recipient : Adalvo

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          07

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : AmbioPharm will manufacture the active pharmaceutical ingredient exclusively for Upsher-Smith. A contract manufacturing organization will exclusively supply Upsher-Smith with the finished product for sale in the United States.

                          Product Name : Acthar

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          July 08, 2020

                          Lead Product(s) : Corticotropin

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Upsher-Smith Laboratories

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank